Treatment of Chagas disease

dc.creatorApt Baruch, Werner
dc.date.accessioned2019-05-29T13:59:12Z
dc.date.available2019-05-29T13:59:12Z
dc.date.created2019-05-29T13:59:12Z
dc.date.issued2017
dc.identifierEn: American Trypanosomiasis Chagas Disease, pp.751-771, December 2017
dc.identifier10.1016/B978-0-12-801029-7.00032-0
dc.identifierhttps://repositorio.uchile.cl/handle/2250/169166
dc.description.abstractAlthough Chagas disease has existed for at least 9000 years, its treatment is recent: the internationally accepted drugs nifurtimox and benznidazole date from the 1970s. Both drugs are effective in acute cases, in congenital cases, in reactivation of chronic cases, and in new chronic cases. Its usefulness in chronic cases has not been shown, except in young women of childbearing age where it has prevented congenital infection and in some cases prevented the development of heart disease. In chronic chagasic cardiopathy benznidazole doesn’t improve the clinical course of the disease. Both drugs cause at least 30% of secondary effects.
dc.languageen
dc.publisherElsevier
dc.sourceAmerican Trypanosomiasis Chagas Disease
dc.subjectBenznidazole
dc.subjectChagas disease
dc.subjectNifurtimox
dc.subjectPosaconazole
dc.subjectRavuconazole
dc.subjectTreatment
dc.titleTreatment of Chagas disease
dc.typeCapítulo de libro


Este ítem pertenece a la siguiente institución